23:22 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting DGAT1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, levels of DGAT1 were higher in CD4 + T cells from the...
20:48 , Oct 5, 2018 |  BC Week In Review  |  Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
14:29 , Oct 3, 2018 |  BC Extra  |  Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
14:55 , Jun 26, 2018 |  BC Extra  |  Company News

Roche’s Kornowski joining Gurnet Point

Healthcare investor Gurnet Point Capital named Sophie Kornowski a senior partner with the firm. The news comes less than a week after Roche (SIX:ROG; OTCQX:RHHBY) said Kornowski was leaving the Swiss pharma, where she was...
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
00:30 , Jun 9, 2017 |  BC Extra  |  Company News

Management tracks

Neurological diseases play Flex Pharma Inc. (NASDAQ:FLKS) said Christoph Westphal will step down as CEO, effective July 3. He will remain chairman. President of R&D William McVicar will be interim CEO. Cancer company ViraTherapeutics GmbH...
07:00 , Jul 22, 2016 |  BC Extra  |  Company News

Management tracks

Boston Pharmaceuticals (Cambridge, Mass.) named Ian Sanderson CFO. He was CFO at Catabasis Pharmaceuticals Inc. (NASDAQ:CATB). Boston plans to in-license products that are in preclinical or early clinical testing, develop them through Phase II proof-of-concept,...
08:00 , Nov 23, 2015 |  BioCentury  |  Finance

Community chorus

Newly formed Boston Pharmaceuticals is armed with $600 million to occupy one section of the drug development continuum: IND through Phase II proof of concept. To do so, the company plans to amass 20-25 assets...
01:56 , Nov 20, 2015 |  BC Extra  |  Top Story

Boston Pharmaceuticals debuts with $600M

Gurnet Point Capital formed Boston Pharmaceuticals (Cambridge, Mass.) and committed $600 million with which the newco intends to build a portfolio of 20-25 assets. Boston Pharmaceuticals plans to in-license products that are in preclinical or...